Shares of Mineralys Therapeutics, Inc. (MLYS) surged nearly 65% on Monday morning after the clinical-stage biopharmaceutical company announced positive topline results from Launch-HTN and Advance-HTN pivotal trials of Lorundrostat for the treatment of uncontrolled or resistant hypertension.
MLYS is currently trading at $17.31, up $6.79 or 64.70%, on the Nasdaq. The stock opened its trading at $14.13 after closing Friday at $10.52. The stock has traded between $8.24 and $15.64 in the past 52-week period.
The company announced positive topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN).
Both trials successfully achieved statistical significance and were clinically meaningful in their pre-specified primary efficacy endpoints and demonstrated a favorable safety and tolerability profile.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.